EP0748313A4 - Cytokine inhibiting imidazole substituted hydroxamic acid derivatives - Google Patents

Cytokine inhibiting imidazole substituted hydroxamic acid derivatives

Info

Publication number
EP0748313A4
EP0748313A4 EP95912688A EP95912688A EP0748313A4 EP 0748313 A4 EP0748313 A4 EP 0748313A4 EP 95912688 A EP95912688 A EP 95912688A EP 95912688 A EP95912688 A EP 95912688A EP 0748313 A4 EP0748313 A4 EP 0748313A4
Authority
EP
European Patent Office
Prior art keywords
acid derivatives
hydroxamic acid
substituted hydroxamic
imidazole substituted
cytokine inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95912688A
Other languages
German (de)
French (fr)
Other versions
EP0748313A1 (en
Inventor
James Simpson Frazee
John Gerald Gleason
Brian Walter Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0748313A1 publication Critical patent/EP0748313A1/en
Publication of EP0748313A4 publication Critical patent/EP0748313A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP95912688A 1994-03-03 1995-03-03 Cytokine inhibiting imidazole substituted hydroxamic acid derivatives Withdrawn EP0748313A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9404046 1994-03-03
GB9404046A GB9404046D0 (en) 1994-03-03 1994-03-03 Novel compounds
PCT/US1995/002606 WO1995023790A1 (en) 1994-03-03 1995-03-03 Cytokine inhibiting imidazole substituted hydroxamic acid derivatives

Publications (2)

Publication Number Publication Date
EP0748313A1 EP0748313A1 (en) 1996-12-18
EP0748313A4 true EP0748313A4 (en) 1997-06-11

Family

ID=10751186

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95912688A Withdrawn EP0748313A4 (en) 1994-03-03 1995-03-03 Cytokine inhibiting imidazole substituted hydroxamic acid derivatives

Country Status (4)

Country Link
EP (1) EP0748313A4 (en)
JP (1) JPH09509940A (en)
GB (1) GB9404046D0 (en)
WO (1) WO1995023790A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
DE69620639T2 (en) * 1995-11-22 2002-10-17 Darwin Discovery Ltd., Cambridge MERCAPTOALKYLPEPTIDYL COMPOUNDS WITH AN IMIDAZOLE SUBSTITUENT AND THEIR USE AS INHIBITORS OF THE MATRIX METALLOPROTEINASES (MMP) AND / OR THE TUMOR NECROSIS FACTOR (TNF)
EP0873304B1 (en) 1995-11-23 2001-09-05 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CA2263154A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
CZ298048B6 (en) 1996-09-10 2007-06-06 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives and pharmaceutical composition containing thereof
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2002041886A1 (en) * 2000-11-23 2002-05-30 British Biotech Pharmaceuticals Ltd Ydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections
US6716861B2 (en) 2000-12-21 2004-04-06 Pfizer, Inc. 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors
GB0031321D0 (en) * 2000-12-21 2001-02-07 Pfizer Ltd Treatment
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
GB0204159D0 (en) * 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
AU2003227952A1 (en) * 2003-05-17 2004-12-03 British Biotech Pharmaceuticals Ltd Metalloproteinase inhibitors
CN114957160B (en) * 2022-03-28 2024-08-23 北京理工大学 2,4, 5-Trisubstituted thiazole compound, preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005716A1 (en) * 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
WO1994002446A1 (en) * 1992-07-23 1994-02-03 British Biotech Pharmaceuticals Limited Natural amino acid derivatives as metalloproteinase inhibitors
WO1994021625A1 (en) * 1993-03-16 1994-09-29 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK77487A (en) * 1986-03-11 1987-09-12 Hoffmann La Roche hydroxylamine
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005716A1 (en) * 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
WO1994002446A1 (en) * 1992-07-23 1994-02-03 British Biotech Pharmaceuticals Limited Natural amino acid derivatives as metalloproteinase inhibitors
WO1994021625A1 (en) * 1993-03-16 1994-09-29 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAPMAN K.T. ET AL.: "Inhibition of metrix metalloproteinases by N-carboxyalkyl peptides", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 26, 24 December 1993 (1993-12-24), pages 4293 - 4301 *
GORDON T. ET AL.: "Peptide azoles: A new class of biologically-active dipeptide mimetics", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 3, no. 5, May 1993 (1993-05-01), PERGAMON PRESS, OXFORD, pages 915 - 920, XP000917229, DOI: doi:10.1016/S0960-894X(00)80692-7 *
See also references of WO9523790A1 *

Also Published As

Publication number Publication date
GB9404046D0 (en) 1994-04-20
EP0748313A1 (en) 1996-12-18
WO1995023790A1 (en) 1995-09-08
JPH09509940A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
HUP0002960A3 (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
PL331895A1 (en) Arylosulphonylamino derivatives of hydroxamic acid
PL320215A1 (en) Triazolyl derivatives
EP0748313A4 (en) Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
GB9504065D0 (en) Poly-pyrrolecarboxamidonaphthalenic acid derivatives
GB9411598D0 (en) Hydroxamic acid derivatives
IL110042A0 (en) Imidazole derivatives
HU9301554D0 (en) 1-(3-halogen-4-trifluoro-methyl-phenyl)-tetrazolinone derivatives
ZA93190B (en) Benzofuranyl- and thiophenylmethylthio-alkanecarboxylic acid derivatives
EP0774965A4 (en) Phenoxyphenylacetic acid derivatives
HU9503783D0 (en) Squvalen syntetase inhibitors
ZA9510888B (en) 3-aryl-tetronic acid derivatives
HUP9903892A3 (en) Hydroxamic acid derivatives
EP0581165A3 (en) Acrylamide derivatives as antirussive agent
HU9300544D0 (en) Sulfobenzyil-substituted imidazolyl-propane acid derivatives
ZA93125B (en) Quinolone- and naphthyridone-carboxylic acid derivatives
HU9204001D0 (en) New imidazole derivatives
ZA95301B (en) Furazancarboxylic acid derivatives
HU9300540D0 (en) Sulfonyl-benzyl substituted imidazole derivatives
GB9408183D0 (en) Hydroxamic acid derivatives
HU9401969D0 (en) Hydroxamic acid derivatives
ZA933957B (en) Hydroxamic acid derivatives
HRP930980A2 (en) Hydroxamic acid derivatives
ZA968751B (en) Fluoromethoxyacrylic acid derivatives
GB9402815D0 (en) Polypyrrolecarboxamidonaphthalenic acid derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 19970424

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19990702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010214